Vaxcyte Q1 EPS $(0.85) Beats $(1.09) Estimate
Portfolio Pulse from Benzinga Newsdesk
Vaxcyte (NASDAQ:PCVX) reported Q1 earnings with losses of $(0.85) per share, surpassing the analyst consensus estimate of $(1.09) by 22.02%. However, this represents a 21.43% increase in losses compared to $(0.70) per share from the same period last year.

May 08, 2024 | 9:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaxcyte's Q1 earnings report showed a smaller loss than expected, but an increase in losses year-over-year.
Beating the EPS estimate typically has a positive short-term impact on a company's stock price as it indicates better-than-expected financial health. However, the increase in losses year-over-year might temper investor enthusiasm, suggesting a cautious optimism.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100